Download these helpful INQOVI resources:

Codes relating to the use of INQOVI

The diagnostic codes contained in this section are designed to provide important reimbursement information that will be helpful for your pharmacy when ordering INQOVI. ICD codes continually change, so it is recommended that you consult your ICD-10 code book or contact the payer for coding and billing guidance.

Formulation Packaging NDC
35 mg decitabine and 100 mg cedazuridine 5-tablet blister pack 64842-0727-9

Please contact an authorized distributor or one of the specialty pharmacies listed on the Specialty Pharmacies tab for AWP and WAC pricing.

AWP=average wholesale price; NDC=National Drug Code; WAC=wholesale acquisition cost.

Diagnosis codes for Myelodysplastic Syndromes (MDS)

ICD‑10‑CM Description
D46.0 Refractory anemia without ring sideroblasts, so stated

Refractory anemia without sideroblasts, without excess of blasts
D46.1 Refractory anemia with ring sideroblasts RARS
D46.2 Refractory anemia with excess of blasts RAEB
D46.20 Refractory anemia with excess of blasts, unspecified RAEB NOS
D46.21 Refractory anemia with excess of blasts 1 RAEB 1
D46.22 Refractory anemia with excess of blasts 2 RAEB 2
D46.A Refractory cytopenia with multilineage dysplasia
D46.B Refractory cytopenia with multilineage dysplasia and ring sideroblasts RCMD R5
D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality

Myelodysplastic syndrome with 5q deletion 5q minus syndrome NOS
D46.4 Refractory Anemia, unspecified
D46.Z Other myelodysplastic syndromes EXCLUDES chronic myelomonocytic leukemia (C93.1-)
D46.9 Myelodysplastic syndrome, unspecified

Myelodysplasia NOS

ICD‑10‑CM EXPERT: Diagnosis codes for Providers & Facilities, AAPC, 2020, p. 505. This information is not intended as coverage or coding advice and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Each healthcare professional is responsible for ensuring that all coding is accurate and appropriate.

Diagnosis codes for Chronic Myelomonocytic Leukemia (CMML)

ICD‑10‑CM Description
C93.1 Chronic myelomonocytic leukemia

Chronic monocytic leukemia



CMML with eosinophilia
C93.10 Chronic myelomonocytic leukemia not having achieved remission

Chronic myelomonocytic leukemia with failed remission

Chronic myelomonocytic leukemia NOS
C93.11 Chronic myelomonocytic leukemia, in remission
C93.12 Chronic myelomonocytic leukemia, in relapse

ICD‑10‑CM EXPERT: for Providers & Facilities, AAPC, 2020, p. 494.

INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated,de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringedsideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2,and high-risk International Prognostic Scoring System groups.

â„¢ logo

Taiho Oncology Patient Support™ for you and your patients

Taiho Oncology Patient Support™ offers personalized services to help give patients, caregivers and healthcare professionals access to Taiho Oncology products. This includes insurance coverage determination and help with medication affordability. For more information, please visit or refer patients to

Meeting the access needs of your patients
Getting patients access to their medicine is an important step. Taiho Oncology Patient Support™ strives to make this process as simple as possible.

Insurance icon

Help Accessing Prescribed Treatment*

Assistance with insurance, including benefits verification, prior authorization, appeals support, and more.

Specialty pharmacy prescription coordination icon

$0 Co-Pay Financial Assistance*

Identifying options for financial support based on current coverage. See below for more details.

Personalized Nurse Support icon

Nurse Support

One-on-one educational support for patients, available via opt-in.

Taiho Oncology Patient Support Co-pay Program

Your eligible patients may pay as little as $0

Eligible, privately insured patients can enroll in the Taiho Oncology Patient Support Co-pay Program™, which may help reduce out-of-pocket expenses to $0* for their treatment with INQOVI.

To determine patient eligibility, go to or call 1-844-TAIHO-4U (1-844-824-4648)

Support starts with an easy-to-complete Enrollment Form that can be downloaded at

To register or learn more, visit or refer patients to or call 1-844-TAIHO-4U (1-844-824-4648) Monday to Friday,
8 AM to 8 PM ET.

*Visit to see full eligibility criteria.

Restrictions and eligibility: Offer valid in the US, Puerto Rico, and US territories only. Only valid for patients with private insurance. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefits plan, Tricare, or other federal or state programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, this offer is not valid and the patient cannot use this offer. By presenting or accepting this benefit, patient and pharmacist agree not to submit claim for reimbursement under the above programs. Patient further agrees to comply with any and all terms of his or her health insurance contract requiring notification to his or her payer for the existence and/or value of this offer. It is illegal to or offer to sell, purchase, or trade this benefit. Maximum reimbursement limits apply; patient out-of-pocket expense may vary. Taiho Oncology, Inc. reserves the right to rescind, revoke or amend this offer at any time without notice.

If selected on the Patient Enrollment Form, a Nurse Navigator will be assigned to provide telephone support and will address general inquiries about INQOVI treatment.

INQOVI Treatment Kit

The INQOVI Treatment Kit provides support for
patients and their caregivers.

The kit includes:


A comprehensive patient brochure


Accompanying caregiver brochure


Blister pack opener with instruction card


Health journal


Advocacy support brochure

Patient advocacy organizations

These organizations offer patients information, support, and community. Feel free to share the following resources with your patients:

The Myelodysplastic Syndromes (MDS) Foundation Inc.

Visit or call 1-800-MDS-0839 (1-800-637-0839)

The Aplastic Anemia and MDS International Foundation (AAMDSIF)

Visit or call 1-800-747-2820

The Leukemia & Lymphoma Society (LLS)

Visit or call 1-800-955-4572

Reference: 1. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022

Previous Page